Publicaciones en las que colabora con Santos Castañeda Sanz (28)

2024

  1. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  2. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register

    RMD open, Vol. 10, Núm. 1

  3. Sex-specific impact of inflammation on traditional cardiovascular risk factors and atherosclerosis in axial spondyloarthritis. A multicentre study of 913 patients

    RMD open, Vol. 10, Núm. 2

2023

  1. Cranial and extracranial giant cell arteritis do not exhibit differences in the IL6 -174 G/C gene polymorphism

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 910-915

  2. Cranial and extracranial large-vessel giant cell arteritis share a genetic pattern of interferon-gamma pathway

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 864-869

  3. Mucosal Immune Defence Gene Polymorphisms as Relevant Players in the Pathogenesis of IgA Vasculitis?

    International Journal of Molecular Sciences, Vol. 24, Núm. 17

  4. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

  5. Sex differences in cardiovascular and disease-related features in axial spondyloarthritis. A multicenter study of 912 patients

    Seminars in Arthritis and Rheumatism, Vol. 60

2022

  1. Cardiovascular and disease-related features associated with extra-articular manifestations in axial spondyloarthritis. A multicenter study of 888 patients

    Seminars in Arthritis and Rheumatism, Vol. 57

  2. Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients

    Seminars in Arthritis and Rheumatism, Vol. 55

  3. IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

    Journal of Clinical Medicine, Vol. 11, Núm. 19

  4. Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis

    Frontiers in Immunology, Vol. 13

  5. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

  6. Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype

    Clinical and experimental rheumatology, Vol. 40, Núm. 4, pp. 727-733

2021

  1. Author Correction: BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis (Scientific Reports, (2021), 11, 1, (11510), 10.1038/s41598-021-91055-z)

    Scientific Reports

  2. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  3. Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals

    Arthritis Research and Therapy

  4. Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

  5. Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  6. Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 2, pp. 395-403